Author

Raffaella Mercatelli

Institute of Biomedical TechnologiesORCID 0000-0002-3231-0527Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 4 Assay:bulk RNA-seq· 3 Organism:human· 3 Approach:statistical model· 3 Approach:experimental assay· 2 Research Focus:metabolism & bioenergetics· 2 Assay:metabolomics· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Elena LevantiniiD· 4 shared Emilia BramantiiD· 4 shared Eva Cabrera San MillániD· 4 shared Giorgia MaroniiD· 4 shared Alice ChiodiiD· 3 shared Ettore MoscaiD· 3 shared Azhar AliiD· 2 shared Beatrice CampanellaiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Elena LevantiniORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Longitudinal per-lesion in vivo imaging reveals allele-dependent resistance evolution in EGFR-mutant lung cancer

Eva Cabrera San Millán, D M Panetta, Paolo Armanetti, Mauro Quaglierini, Alessandro Zega, Raffaella Mercatelli, Emilia Bramanti, L Menichetti, Giorgia Maroni, Elena Levantini

This study uses longitudinal in vivo imaging to show how different EGFR mutations affect resistance evolution in lung cancer lesions under therapy.

bioRxiv · Apr 18, 2026 · PreprintCancer Biology

The two sides of resistance: aggressiveness and mitotic instability as the Achilles heel of Osimertinib-resistant NSCLC

Paolo Armanetti, Eva Cabrera San Millán, Raffaella Mercatelli, Chiara Cavallini, Alice Chiodi, Ettore Mosca, Arianna Consiglio, Nicola Losito, Luca Menichetti, Emilia Bramanti, Azhar Ali, Elena Levantini, Giorgia Maroni

This study identifies BMI1 as a driver of Osimertinib resistance in NSCLC by promoting mitotic instability and aggressiveness, and shows that targeting BMI1 with Unesbulin can suppress tumor growth.

bioRxiv · Sep 25, 2025 · PreprintCancer Biology

Deciphering the Role of Acetate in Metabolic Adaptation and Drug Resistance in Non-Small Cell Lung Cancer

Giorgia Maroni, Eva Cabrera San Millán, Beatrice Campanella, Massimo Onor, Giovanni Cercignani, Beatrice Muscatello, Giulia Braccini, Raffaella Mercatelli, Alice Chiodi, Ettore Mosca, Elena Levantini, Emilia Bramanti

This study identifies a metabolic adaptation in osimertinib-resistant NSCLC cells involving acetate production via a PAA shunt, which supports redox balance and bioenergetics.

bioRxiv · Jul 4, 2025 · PreprintBiochemistry

Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of Resistance

Giorgia Maroni, Eva Cabrera San Millán, Raffaella Mercatelli, Alice Chiodi, Beatrice Campanella, Massimo Onor, Letizia Modeo, Giulia Braccini, Giovanni Cercignani, Azhar Ali, Ettore Mosca, Emilia Bramanti, Elena Levantini

This study identifies metabolic reprogramming in osimertinib-resistant EGFR-mutant NSCLC, highlighting the pyruvate-acetaldehyde-acetate pathway and mitochondromic alterations as key drivers of resistance.

bioRxiv · Jun 27, 2025 · PreprintCancer Biology